Hemophilia B Epidemiology Forecast 2026-2035

Read more about this report - Request a Free Sample

Hemophilia B Epidemiology Forecast Report Coverage

Expert Market Research's “Hemophilia B Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of hemophilia B. It projects the future incidence and prevalence rates of hemophilia B cases across various populations. The study covers age and type as major determinants of the hemophilia B population. The report highlights patterns in the prevalence of hemophilia B over time and projects future trends based on multiple variables.

Hemophilia B Understanding: Disease Overview

Hemophilia B is defined as a rare inherited blood disorder that causes easy bruising and bleeding due to the deficiency of functional plasma coagulation factor IX. The severity of this condition depends on the amount of factor IX present in the blood and its activity. As an X-linked recessive disorder, hemophilia B primarily affects males, with carrier mothers passing the defective gene to sons.

Common hemophilia B symptoms include bleeding that starts without cause, nosebleeds, and bleeding from tooth extraction and surgery, among others. Hemophilia B can be fatal without treatment, as it can lead to spontaneous or prolonged hemorrhages.

Hemophilia B Epidemiology Perspective 

The hemophilia B epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the hemophilia B epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for Hemophilia B and its trends. The hemophilia B detailed epidemiology segmentation is broken down into specific categories, such as the total diagnosed cases across different age groups and patient pools.

• The prevalence and incidence of hemophilia B are estimated to be 5.3 cases per 100,000 males and 1 case per 25,000 to 30,000 male births , respectively.
• As per the National Institute for Health and Care Excellence  (NICE), there were 2,069 people living with hemophilia B in the United Kingdom during 2022/2023. Out of these, 374 had the severe form of the condition, and 351 had a moderate form,  
• Studies show that hemophilia B is less common compared to hemophilia A, with hemophilia B comprising around 14% of all hemophilia cases .
• Being an X-linked recessive disorder, hemophilia B occurs predominantly in males. However, an estimated 10 to 25%  of hemophilia B carrier females are reported to experience mild symptoms, according to the National Organization for Rare Disorders (NORD).
• Based on the plasma levels of factor IX, hemophilia B can be classified as mild (6-40%), moderate (1-5%), or severe (< 1%). Studies show that around 50%  of the hemophilia B-affected population has factor IX levels greater than 1%.

Read more about this report - Request a Free Sample

Country-wise Hemophilia B Epidemiology Segment

The hemophilia B epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of hemophilia B varies significantly between countries due to differences in genetic prevalence, healthcare infrastructure, and access to diagnostic and treatment facilities, among others. As per the US Centers for Disease Control and Prevention, hemophilia is reported to occur in 1 in 5,000 live births. Further, approximately 30,000 to 33,000 individuals  are estimated to be affected by hemophilia in the United States.

Hemophilia B: Treatment Overview

Factor replacement therapy is a widely used treatment option for hemophilia B. Factor IX concentrates are infused into a vein to address the deficiency of the clotting factor IX. Hemophilia B therapeutics include Nonacog alfa (BeneFix) injections, which are an engineered version of clotting factor IX. They are often recommended twice a week to prevent bleeding in the affected patients. 

In mild or moderate hemophilia B cases, factor replacement therapy is usually required at the time of surgery, whereas in severe cases, patients may need regular injections of concentrated clotting factor IX. Recent advances have introduced extended half-life (EHL) factor IX products, which require less frequent dosing. Additionally, in 2024 , the FDA approved Beqvez, a gene therapy that enables the body to produce its own factor IX, potentially offering long-term or even lifelong control with a single treatment.

Key Questions Answered

• What are the key findings of hemophilia B epidemiology in the 8 major markets?
• What will be the total number of patients with hemophilia B across the 8 major markets during the forecast period?
• What was the country-wise hemophilia B epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of hemophilia B cases during the forecast period of 2026-2035?
• Which key factors would influence the shift in the patient population of hemophilia B during the forecast period of 2026-2035?
• What are the currently available treatments in the global hemophilia B market?
• What are the disease risks, signs, symptoms, and unmet needs of hemophilia B?

Scope of the Hemophilia B Epidemiology Report

• The hemophilia B epidemiology forecast covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of Hemophilia B based on several factors.
• The Hemophilia B Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The hemophilia B report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

Global Haemophilia Treatment Market